Purified Factor VIII: A High Yield Production Method for Routine Blood Banks

Welbergen, H.; Das, P. C.; Sibinga, C. Th. Smit

doi:10.1007/978-94-009-7692-4_25

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the patients (PH) is known to develop allergic reactions, when treated with non-ABO group specific cryoprecipitate. As the average immunoglobulin content of the preparation is about 1-2% of total protein in the final product (12,13,15,16) and the alloagglutinin titers range from 8-32, we may expect the product to be relatively safe, comparing favour ably with the average commercial concentrates. Neither he nor the other patients showed any allergic side-effects or change in haematology parameters over the total period of testing.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

Sibinga¹,

Daenen

Vanimhoff

et al. 1984

Thromb Haemost

View full text Add to dashboard Cite

SummaryNew approaches and techniques for improving source material collection and Factor VIII production at Blood Bank level have been reported recently.Heparin has been shown to be of importance in increasing yields and stability of FVIII in the purification and concentration process. Work has been done to develop on a routine scale the heparin double cold precipitation technique for the production of a freeze-dried high yield purified FVIII concentrate.The product has been tested clinically in 4 severe hemophilia A patients for recovery, half-life and acute side-effects, using two dosages over 8 infusions. There was no significant difference between the two dosages. Mean recovery 99.1% and mean halflife 8 hr, ranging from 6.5 to 10.3 hr.No side-effects were observed.These results justify further exploration of the potential of heparin for high yield purified FVIII production.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Combining the advantages of both the principle of thaw siphoning (3-6) and fast-thaw methodology (7) together with the important effects of heparin (8,9) and calcium ions (10) on FVIII preservation, have led to the development of new techniques for purifying FVIII at high yields from routine blood donations (11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

Sibinga¹,

Daenen

Vanimhoff

et al. 1984

Thromb Haemost

View full text Add to dashboard Cite

show abstract

Heparin and Factor VIII

Sibinga¹,

Das²

1984

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

New approaches and techniques for improving source material collection and fac Jr '111 production at Blood Bank level have been reported recently. Heparin has shown to be of great importance in increasing both yield and stability of factor VIII in the purification and concentration process. Work has been done t o develop on a routine scale a heparin double cold-precipitation technique for the production of freeze-dried high yield purified factor VIII concentrate. As a spin-off of the method red cell concentrate (RCC) and cryosupernatant plasma (SDP), both containing small amounts of heparin besides the standard CPDA-1 anticoagulant, are recovered for clinical use. Results of the tests done: RCCin wino: Normal Adenosin Tri-Phosphate (ATP), 2 3 Di-Phospho-Glycerate (DPG) and shelf-life, Heparin 0.7 IU/ml (20.3). -in wiwo: Normal half slCr-survival, no side effects. SDPin witro: Protein and chemical analysis normal, shelf-life normal, Heparin 3.5 IU/ml (5 0.7). in wivo: No side-effects, mild effect on activated Partial Thromboplastin Time (aPTT) 5 minutes post transfusion. Factor VIII concentratein wirro: Yield 56.2 (+ 8.2) percent, purity 0.8 (50.15) FVI1I:C IU/mg protein, potency 25.2 (+3.2), FVII1:C IU/ml Heparin 6.2 (?.0.7) IU/ml. -in wivo: Normal recoveries and half-lifes after injection of 15-20 IU/kg in 4 severe hemophilia A patients.This heparin small pool high yield principle is expected to have great impact on availability, access t o and safety of adequate treatment in hemophilia in the future.

show abstract

Purified Factor VIII: A High Yield Production Method for Routine Blood Banks

Cited by 2 publications

References 7 publications

Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

Heparin and Factor VIII

Contact Info

Product

Resources

About